Topic: Latest News | Hospital Pharmacy Europe
This site is intended for health professionals only
Tuesday 21 August 2018
Share |

Topic: Latest News

August 14, 2018
The prescribing safety assessment (PSA) could benefit pre-registration pharmacy students who want to become independent prescribers, a study has concluded.

The prescribing safety assessment (PSA) could benefit UK pre-registration pharmacy students who want to become independent prescribers, a study has concluded.
 
The PSA is a 60-minute evaluation of 30 questions on writing and reviewing new prescriptions, calculating drug doses and identifying and avoiding adverse drug reactions and medication errors, among others.
 

August 8, 2018
Senior clinicians will be able to legally prescribe cannabis-derived medicines this autumn, the Home Office has announced.

Senior clinicians will be able to legally prescribe cannabis-derived medicines this autumn, the UK's Home Office has announced.
 

August 8, 2018
New restricted indications on prescribing Esmya (ulipristal acetate) for symptoms of uterine fibroids have been put in place by the UK’s medicines watchdog

New restricted indications on prescribing Esmya (ulipristal acetate) for symptoms of uterine fibroids put in place by the UK’s medicines watchdog now replace instructions that the drug should not be prescribed to any new patients.
 

August 6, 2018
New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.

New patient groups with cancer-associated venous thromboembolism (VTE) could benefit from taking once-daily oral LIXIANA (edoxaban), a recent analysis has said.
 
Manufacturer Daiichi Sankyo announced today (6 July) it had published a new analysis on the clinical presentation, course and outcome of bleeding events in Thrombosis and Haemostasis, and the associated tumour types from the Hokusai-VTE cancer study.
 

August 2, 2018
The Government should consider the economic as well as health benefits of vaccinating people against flu, according to research by a think tank

The Government should consider the economic as well as health benefits of vaccinating people against flu, according to research by a think tank.
 
Research by the International Longevity Centre – UK (ILC-UK) argued that flu can adversely affect productivity within the economy. The biggest economic benefit of vaccinating against the condition is the reduction of lost employment and care giving costs, which total between £90m and £270m , it said.
 

August 1, 2018
More than 3000 participants from 75 countries gathered in Gothenburg for the 23rd congress of EAHP. The meeting covered a range of hospital pharmacy activities and highlights included biosimilars in oncology, advanced therapy medicinal products and post-operative analgesia
Anna de Goede
Anna de Goede
 
Richard Langford
Richard Langford
 
Eric Viel
Eric Viel
July 26, 2018
Who is Matt Hanncock and what is his background?

Matt Hancock MP was appointed digital, culture, media and sport secretary in January 2018 having been a junior minister in the department since July 2016. He was first elected an MP in the 2010 general election in the West Suffolk constituency.
 
Before entering parliament, he worked as an economist at the Bank of England and as chief of staff to the shadow chancellor.
 
He has little health background, with no obvious links to the NHS.
 

July 26, 2018
How will Matt Hancock’s healthcare priorities benefit the NHS?

Last week, health and social care secretary Matt Hancock gave his first speech at West Suffolk Hospital where he revealed three key priorities for the NHS: technology, workforce and prevention.
 
Speaking before the Health and Social Care Committee yesterday, he also gave more information on the work he intends to do.
 
So what do the priorities mean for the health service?
 
Technology focus
 

July 18, 2018
Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.

Up to 42% of UK medicines may not be able to market their products in the European Union (EU) post-Brexit, a survey from the European Medicines Agency (EMA) has revealed.
 
The EMA said marketing authorisation holders for 58% of 693 centrally authorised products (CAPs) are on track to ensure they can continue to market their products once the UK leaves the EU in March 2019.
 

July 18, 2018
The UK’s National Health Service turned 70 this month, and while we celebrate the achievements of one of the nation’s most valuable institutions, it’s also the perfect opportunity to pinpoint the role that pharmacy has played in the NHS during those decades.

The role of pharmacists in the NHS has, unsurprisingly, evolved quite a bit since its inception. Growing from what was originally a supply service to become a clinical practice in hospitals, and with a range of new roles in primary care, pharmacists are now recognised as a valuable part of the multidisciplinary clinical team.
 

July 12, 2018
Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.

Patients with rare autoinflammatory diseases in the UK have a new treatment option with the launch of Sobi’s Kineret following approval from the European Medicines Agency (EMA) earlier this year.
 
The drug is already licensed in the UK for treating rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS). It will now be available to patients with adult onset stills disease (AOSD) and systemic-onset juvenile idiopathic arthritis (SIJA), which impacts children under the age of 16 years.
 

July 11, 2018
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.

The European Commission (EC) has approved a label change for Simponi (golumumab) allowing early dose optimisation in patients with ulcerative colitis (UC).
 
The drug will be now available for dose optimisation in UC patients with a body weight of less than 80kg, who do not respond to induction therapy.
 

July 11, 2018
The European anti-counterfeiting measures will come into force in February. Léa Legraien gives pharmacists all the information they need to make sure they’re ready

The European anti-counterfeiting measures will come into force in February. Lea Legraien gives pharmacists all the information they need to make sure they’re ready 
 
The Falsified Medicines Directive (FMD) will come into force on 9 February 2019 in the UK, as mandated by the European Commission (EC), to tackle counterfeit medicines and improve patient safety.
 

July 10, 2018
In draft guidance published on 9 July NICE recommended that healthcare professionals prescribe antibiotics to people with COPD only when suffering from severe acute exacerbation.

Antibiotics should be restricted when used for chronic obstructive pulmonary disease (COPD), the National Institute for Health and Care and Excellence (NICE) has urged.
 

July 5, 2018
Cimzia can be used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, following label extension by European Medicines Agency (EMA)

The European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol) therapy, Belgian biopharmaceutical company UCB has announced.
 
The extension allows Cimzia’s use for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
 

July 4, 2018
A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.

A clinical trial to treat female diffuse hair loss has been kick started by US regenerative medicine company Histogen.
 
This month [June 2 2018], the organisation announced the launch of a Phase I Clinical Trial of its lead product, Hair Stimulating Complex, to treat the condition.
 

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

June 28, 2018
First patient with metastatic breast cancer receives treatment to look at anti-tumour effect and tolerability using new drug response predictor

A drug trial on a patient with metastatic breast cancer selected by a new drug response predictor has been launched.
 

June 28, 2018
First cannabinoid prescription medicine to be approved in the US endorses Epidiolex to treat two rare forms of childhood-onset epilepsy

The first cannabinoid prescription in the US has been given the green light by the US Food and Drug Administration (FDA) [June 25 2018].
 
GW Pharmaceuticals’ Epidiolex has been approved to treat two rare forms of childhood onset epilepsy - Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome.
 

June 27, 2018
Oral Semaglutide demonstrates significant reduction in blood sugar versus placebo in trial

A once-daily tablet could reduce blood sugar in adults with type 2 diabetes, a study has shown.
 
Oral semaglutide, an investigational GLP-1 analogue from global healthcare company Novo Nordisk,achieved “significant reductions in blood sugar versus placebo in adults with type 2 diabetes”, according to the PIONEER 1 phase 3a trial.
 
The trial evaluated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo as monotherapy over 26 weeks in adults with type 2 diabetes. [1] 
 

June 26, 2018
The guidance recommends co-prescribing cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease, building on broader prescribing advice from the 2006 guidelines. A spokesperson from NICE said that the change was in response to new trials, including the DOMINO-AD trial in the UK.

The UK’s National Institute for health and Care and Excellence (NICE) has updated dementia guidelines to  include revised prescribing advice, new measures for patients suffering from dementia with lewy bodies (DLB) and a move to primary care treatment.
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.

Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.
 
The EC granted the company a full marketing authorisation for the drug based on the overall survival date from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (PH-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine